Anti-AZU1 Antibody (Rabbit Polyclonal antibody) General Information
Reacts with: Human
Recombinant Human AZU1 protein (Catalog#10660-H08H)
Produced in rabbits immunized with purified, recombinant Human AZU1 (rhAZU1; Catalog#10660-H08H; NP_001691.1; Met 1-Pro 250). Total IgG was purified by Protein A affinity chromatography.
Polyclonal Rabbit IgG
0.2 μm filtered solution in PBS with 5% trehalose
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Anti-AZU1 Antibody (Rabbit Polyclonal antibody) Validated Applications
**********Please Note: Optimal concentrations/dilutions should be determined by the end user.**********
Anti-AZU1 Antibody Alternative Names
Anti-AZAMP Antibody;Anti-AZU Antibody;Anti-AZU1 Antibody;Anti-CAP37 Antibody;Anti-HBP Antibody;Anti-hHBP Antibody;Anti-HUMAZUR Antibody;Anti-NAZC Antibody
AZU1 Background Information
Azurocidin (AZU1), also known as heparin-binding protein (HBP) or cationic antimicrobial protein 37 (CAP37), is an azurophil granule antibiotic protein, with monocyte chemotactic and antibacterial activity. The Azurophil granules, specialized lysosomes of the neutrophil, contain at least 10 proteins implicated in the killing of microorganisms. Azurocidin is a member of the serine protease family that includes Cathepsin G, neutrophil elastase (NE), and proteinase 3 (PR3), however, Azurocidin is not a serine proteinase since the active site serine and histidine residues are replaced. Neutrophils arriving first at sites of inflammation release Azurocidin, which acts in a paracrine fashion on endothelial cells causing the development of intercellular gaps and allowing leukocyte extravasation. It thus be regarded as a reasonable therapeutic target for a variety of inflammatory disease conditions.
Lindmark A, et al. (1999) Characterization of the biosynthesis, processing, and sorting of human HBP/CAP37/azurocidin. J Leukoc Biol. 66(4): 634-43.Heinzelmann M, et al. (2001) Heparin binding protein (CAP37) differentially modulates endotoxin-induced cytokine production. Int J Surg Investig. 2(6): 457-66.Soehnlein O, et al. (2005) Neutrophil-derived heparin-binding protein (HBP/CAP37) deposited on endothelium enhances monocyte arrest under flow conditions. J Immunol. 174(10): 6399-405.